Earnings Call
Jul 23, 2026
Q2 FY2026
EPS Estimate
5.72
EPS Actual
6.03
Post-Earnings Close
$572.32
Earnings Reaction
+8.7%
Thermo Fisher Scientific delivered a standout second quarter, with organic revenue growth of 5% and adjusted EPS of $6.03, up 13% year-over-year and well ahead of both consensus and the company's own prior guidance. Revenue came in at $11.99 billion, roughly $300 million above internal expectations, driven by a combination of stronger-than-anticipated customer activity, acquisition contributions from Clario and the Filtration and Separation business, and a modest FX tailwind. Adjusted operating margin expanded 90 basis points to 22.8%, reflecting strong volume leverage and productivity gains through the PPI Business System, even as the company absorbed unfavorable mix and continued to fund strategic investments. The quarter was, by management's own characterization, clean, broad-based across segments, geographies, and end markets, with no notable one-time items distorting the picture.
Report generated on Jul 23, 2026
AI-generated earnings analysis. Not investment advice.
Chief Executive Officer
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
Read the full TMO analysis
The complete report, with key themes, analyst Q&A summary, notable quotes, and market context — is free with an account. No password, no card.